Particularly, due to the pathophysiological relevance of ACC2 in lipid metabolic syndrome associated with obesity, diabetes, cancer, and cardiovascular disease, ACC2 activity regulation has been considered as a candidate target for therapeutic interventions, which essentially requires authentic bioengineered recombinant proteins (Abu-Elheiga et al. 2001; Tong 2013; Tong and Harwood 2006). Here, ACACB is linked to obesity due to melanocortin 4 receptor deficiency.